Evotec ex­pands glob­al dis­cov­ery, de­vel­op­ment ops with $300M Ap­tu­it buy­out

Ger­many’s Evotec is beef­ing up its con­tract drug de­vel­op­ment or­ga­ni­za­tion, buy­ing out ri­val Ap­tu­it in a deal that will add hun­dreds of sci­en­tists to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER